Research programme: sustained-release siRNA and microRNA therapeutics - Celsion

Drug Profile

Research programme: sustained-release siRNA and microRNA therapeutics - Celsion

Alternative Names: EGEN-002; GEN 2; Research programme: sustained-release siRNA anticancer therapeutics - Celsion

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EGEN; SurModics
  • Developer Celsion Corporation
  • Class MicroRNAs; Small interfering RNA
  • Mechanism of Action MIRN145-microRNA-inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pulmonary arterial hypertension
  • No development reported Lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Lung-cancer in USA (IV)
  • 01 Mar 2016 Celsion receives patent allowance for TheraSilence™ lung-specific delivery system in USA
  • 12 Mar 2015 Celsion has patent protection for TheraSilenceTM technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top